Emyria Opens Victorian Psychedelic Therapy Clinic With Insurance Funding Active
Emyria hits Q2 CY2026 target with first Victorian Empax clinic now operational
Emyria Limited (ASX: EMD) has activated its first Victorian Empax clinic, commencing first patient treatments and meeting its Q2 CY2026 launch target. The milestone extends Empax clinic operations across three states, with Western Australia, Queensland, and Victoria now all operational. Two funded reimbursement pathways are active at the Victorian site, supported by clinical infrastructure established within Avive Health’s Mornington Peninsula Private Hospital.
When big ASX news breaks, our subscribers know first
Clinic infrastructure, workforce and funded pathways all operational
A purpose-built clinical hub on the Mornington Peninsula
The Victorian Empax clinic is housed within Avive Health’s Mornington Peninsula Private Hospital, with a dedicated 3-bed clinical infrastructure now fully established. Subject to demand growth, an option exists to add a 4th bed in Q4 CY2026.
All key operational workstreams are confirmed as in place, including site readiness, medication supply and dispensing, regulatory requirements, and clinical governance frameworks.
30+ therapists trained and TGA Authorised Prescriber confirmed
The Company recruited and trained more than 30 therapists following a well-supported recruitment campaign. One psychiatrist has received TGA Authorised Prescriber (AP) status, with three additional trained psychiatrists currently in the AP application process.
The pipeline of AP applications is positioned to support increased utilisation as clinic demand builds, with each confirmed AP expanding prescribing capacity at the Victorian site.
Victorian Empax clinic at a glance:
- 3-bed clinic (option for 4th bed in Q4 CY2026)
- 30+ therapists recruited and trained
- 1 TGA Authorised Prescriber confirmed
- 3 additional AP applications in progress
- Dual reimbursement pathways active (Medibank + DVA)
What are reimbursable psychedelic-assisted therapies and why do they matter for investors?
Psychedelic-assisted therapy refers to clinical treatment programmes that use controlled substances, such as MDMA or psilocybin, in conjunction with structured psychological support. Emyria’s model targets patients with post-traumatic stress disorder (PTSD) and treatment-resistant depression, two conditions where conventional treatments have limited effectiveness.
“Reimbursable” means the cost of treatment is funded in whole or in part by a third-party payer, such as a private health insurer or government body, rather than being paid entirely out-of-pocket by the patient. This distinction matters significantly for access and revenue. Self-funded models limit the addressable patient population to those who can afford treatment privately, while reimbursement pathways remove that financial barrier and enable repeatable, volume-driven revenue.
Two payer pathways are currently active across WA, QLD, and VIC: Medibank (private health insurance) and the Department of Veterans’ Affairs (DVA), which funds eligible veterans. Workers Compensation insurers are expected to be added over time, widening the funded patient funnel further.
For investors, reimbursement pathways convert clinical capability into a scalable revenue model. Volume can grow without relying solely on individual out-of-pocket patients, and each additional payer that comes online widens the addressable market.
| Payer Type | Payer Name | Status | Patient Cohort | Geography |
|---|---|---|---|---|
| Private Health Insurer | Medibank | Active | Eligible members | WA, QLD, VIC |
| Government | DVA (Dept. of Veterans’ Affairs) | Active | Veterans | WA, QLD, VIC |
| Workers Compensation | TBC | Expected (future) | Workplace injury/trauma | TBC |
The next major ASX story will hit our subscribers first
On-strategy execution sets the stage for disciplined scale
The Victorian clinic activation marks the beginning of a ramp-up phase rather than a concluded milestone. Referrer engagement is underway and the three pending AP applications represent a near-term catalyst for increased prescribing activity and utilisation growth across the site.
At the network level, Emyria now operates a three-state Empax footprint, with a repeatable revenue model anchored by reimbursable, evidence-based treatments and strong clinical data. The addition of Workers Compensation payers is anticipated to further broaden patient access over time.
Greg Hutchinson, Executive Chair
“We are pleased to have successfully launched our first Victorian Empax clinic and commenced treatments in line with our Q2 CY2026 target. Importantly, we have established the infrastructure, workforce and funded patient pathways required to support early utilisation and a disciplined ramp-up phase.”
Investors watching Emyria’s progress should monitor three near-term indicators: the conversion of pending AP applications into active prescribing, utilisation rates building across all three state clinics, and the onboarding of Workers Compensation insurers as the next reimbursement expansion catalyst.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis so the work is already done. Join 20,000+ subscribers who stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button to start receiving alerts today.